Retroviral vector-mediated gene expression in hematopoietic cells

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 5, 1999, Pages 605-612

  Baum, Christopher ^a   Richters, Anke ^a   Ostertag, Wolfram ^a  

^a LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

Author keywords

Cis elements; Hematopoietic cells; Retroviral; Transcription; Transgene

Indexed keywords

VIRUS VECTOR;

GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSCRIPTION; HEMATOPOIETIC CELL; LENTIVIRINAE; MOUSE; NONHUMAN; RETROVIRUS; REVIEW; TRANSGENE;

ANIMALS; BONE MARROW CELLS; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; RETROVIRIDAE; RNA PROCESSING, POST-TRANSCRIPTIONAL;

EID: 0032692573     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Morrison SJ, Uchida N, Weissman IL: The biology of hematopoietic stem cells. Annu Rev Cell Dev Biol (1995) 11:35-71.
2. Whitley C: Ex vivo gene transfer methods for human blood cells. Curr Res Mol Ther (1998) 1:166-181.
3. Baum C, Stocking C, Wagener T, Eckert HG, Ostertag W: Gene transfer and transgene expression in hematopoietic cells. In: Concepts in Gene Therapy. Strauss M, Barranger JA (Eds), Walter de Gruyter, Berlin (1997):233-265.
4. Baum C, Ostertag W, Stocking C, von Laer D: Retroviral vector design for cancer gene therapy. In: Gene Therapy of Cancer. Lattime E, Gerson S (Eds), Academic Press, San Diego (1999):51-76
5. Feng Y-Q, Alami R, Bouhassira EE: Enhancer-dependent transcriptional oscillations in mouse erythroleukemia cells. Mol Cell Biol (1999) 19:4907-4917.
6. Struhl K: Histone acetlyation and transcriptional regulatory mechanims. Genes Dev (1998) 12:599-606.
7. Matsumoto K, Wassarman KM, Wolffe AP: Nuclear history of pre-mRNA determines the translational activity of cytoplasmic mRNA. EMBO J (1998) 17:2107-2121.
8. Colgan DF, Manley JL: Mechanism and regulation of mRNA polyadenylation. Genes Dev (1997) 11:2755-2766.
9. Cullen BR: Retroviruses as model systems for the study of nuclear RNA export pathways. Virology (1998) 249:203-210.
10. Enver T, Greaves M: Loops, lineage, and leukemia. Cell (1998) 94:9-12.
11. Miller AD, Miller DG, Garcia JV, Lynch CM: Use of retroviral vectors for gene transfer and expression. Methods Enzymol (1993) 217:581-599.
12. Stocking C, Kollek R, Bergholz U, Ostertag W: Long terminal repeat sequences impart hematopoietic transformation properties to the myeloproliferative sarcoma virus. Proc Natl Acad Sci USA (1985) 82:5746-5750.
13. Franz T, Hilberg F, Seliger B, Stocking C, Ostertag W: Retroviral mutants efficiently expressed in embryonal carcinoma cells. Proc Natl Acad Sci USA (1986) 83:3292-3296.
14. Loh TP, Sievert LL, Scott RW: Evidence for a stem cell-specific represser of Moloney murine leukemia virus expression in embryonal carcinoma cells. Mol Cell Biol (1990) 10:4045-4057.
15. Petersen R, Kempler G, Barklis E: A stem cell-specific silencer in the primer-binding site of a retrovirus. Mol Cell Biol (1991) 11:1214-1221.
16. Grez M, Akgün E, Hilberg F, Ostertag W: Embryonic stem cell virus, a recombinant murine retrovirus with expression in embryonic stem cells. Proc Natl Acad Sci USA (1990) 87:9202-9206.
17. Baum C, Hegewisch-Becker S, Eckert HG, Stocking C, Ostertag W: Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol (1995) 69:7541-7547.
18. Rivière I, Brose K, Mulligan RC: Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA (1995) 92:6733-6737.
19. Hawley RG, Lieu FHL, Fong AZC, Hawley TS: Verstaile retroviral vectors for potential use in gene therapy. Gene Ther (1994) 1:136-138.
20. Eckert H-G, Stockschläder M, Just U, Hegewisch-Becker S, Grez M, Uhde A, Zander A, Ostertag W, Baum C: High-dose multidrug resistance in primary human hematopoietic progenitor cells transduced with optimized retroviral vectors. Blood (1996) 88:3407-3415.
21. Pawliuk R, Eaves CJ, Humphries RK: Sustained high-level reconstitution of the hematopoietic system by preselected hematopoietic cells expressing a transduced cell-surface antigen. Hum Gene Ther (1997) 8:1595-1604.
22. Persons DA, Allay JA, Allay ER, Smeyne RJ, Ashmun RA, Sorrentino BP, Nienhuis AW: Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo. Blood (1997) 90:1777-1786.
23. Cheng L, Du C, Lavau C, Chen S, Tong J, Chen BP, Scollay R, Hawley RG, Hill B: Sustained gene expression in retrovirally transduced, engrafting human hematopoietic stem cells and their lympho-myeloid progeny. Blood (1998) 92:83-92.
24. Robbins PB, Skelton DC, Yu XJ, Halene S, Leonard EH, Kohn DB: Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells. Proc Natl Acad Sci USA (1998) 95:10182-10187.
25. Hildinger M, Eckert HG, Schilz AJ, John J, Ostertag W, Baum C: FMEV vectors: Both retroviral long terminal repeat and leader are important for high expression in transduced hematopoietic cells. Gene Ther (1998) 5:1575-1579.
26. van Hennik PB, Verstegen MM, Bierhuizen MF, Limón A, Wognum AW, Cancelas JA, Barquinero J, Ploemacher RE, Wagemaker G: Highly efficient transduction of the green fluorescent protein gene in human umbilical cord blood stem cells capable of cobblestone formation in long-term cultures and multilineage engraftment of immunodeficient mice. Blood (1998) 92:4013-4022.
27. Becker S, Wasser S, Hauses M, Hossle JP, Ott MG, Dinauer MC, Ganser A, Hoelzer D, Seger R, Grez M: Correction of respiratory burst activity in X-linked chronic granulomatous cells to therapeutically relevant levels after gene transfer Into bone marrow CD34+ cells. Hum Gene Ther (1998) 9:1561-1570.
28. Speck NA, Renjifo B, Golemis E, Fredrickson TN, Hartley JW, Hopkins N: Mutation of the core or adjacent LVb elements of the Moloney murine leukemia virus enhancer alters disease specificity. Genes Dev (1990) 4:233-242.
29. Zaiman AL, Nieves A, Lenz J: CBF, Myb, and Ets binding sites are important for activity of the core I element of the murine retrovirus SL3-3 in T-lymphocytes. J Virol (1998) 72:3129-3137.
30. Lewis AF, Stacy T, Green WR, Taddesse-Heath L, Hartley JW, Speck NA: Core-binding factor influences the disease specificity of moloney murine leukemia virus. J Virol (1999) 73:5535-5547.
31. Welsh S, Kay SA: Reporter gene expression for monitoring gene transfer. Curr Opin Biotechnol (1997) 8:617-622.
32. Granger SW, Fan H: In vivo footprinting of the enhancer sequences in the upstream long terminal repeat of Moloney murine leukemia virus: differential binding of nuclear factors in different cell types. J Virol (1998) 72:8961-8970.
33. Speck NA, Baltimore D: Six distinct nuclear factors interact with the 75-base-pair repeat of the Moloney murine leukemia virus enhancer. Mol Cell Biol (1987) 7:1101-1110.
34. Sun W, Graves BJ, Speck NA: Transactivation of the Moloney murine leukemia virus and T-cell receptor beta-chain enhancers by cbf and ets requires intact binding sites for both proteins. J Virol (1995) 69:4941-4949.
35. Nielsen AL, Norby PL, Pedersen FS, Jorgensen P: E-box sequence and context-dependent TAL1/SCL modulation of basic helix-loop-helix protein-mediated transcriptional activation. J Biol Chem (1996) 271:31463-31469.
36. Nielsen AL, Norby PL, Pedersen FS, Jorgensen P: Various modes of basic helix-loop-helix protein-mediated regulation of murine leukemia virus transcription In lymphoid cell lines. J Virol (1996) 70:5893-5901.
37. Grez M, Zörnig M, Nowock J, Ziegler M: A single point mutation activates the Moloney murine leukemia virus long terminal repeat in embryonal stem cells. J Virol (1991) 65:4691-4698.
38. Baum C, Itoh K, Meyer J, Laker C, Ito Y, Ostertag W: The potent enhancer activity of the polycythemic strain of spleen focus-forming virus in hematopoietic cells is governed by a binding site for Sp1 in the upstream control region and by a unique enhancer core motif, creating an exclusive target for PEBP/CBF. J Virol (1997) 71:6323-6331.
39. Barat C, Rassart E: Members of the GATA family of transcription factors bind to the U3 region of Cas-Br-E and graffi retroviruses and transactivate their expression. J Virol (1998) 72:5579-5588.
40. Malik P, Krall WJ, Yu XJ, Zhou C, Kohn DB: Retroviral-mediated gene expression in human myelomonocytic cells: a comparison of hematopoietic cell promoters to viral promoters. Blood (1995) 86:2993-3005.
41. Wang L, Robbins PB, Carbonaro DA, Kohn DB: High-resolution analysis of cytosine methylation in the 5long terminal repeat of retroviral vectors. Hum Gene Ther (1998) 9:2321-2330.
42. Nettelbeck DM, Jérome V, Müller R: A strategy for enhancing the transcriptional activity of weak cell type-specific promoters. Gene Ther (1998) 5:1656-1664.
43. Tsukiyama T, Niwa O, Yokoro K: Analysis of the binding proteins and activity of the long terminal repeat of Moloney murine leukemia virus during differentiation of mouse embryonal carcinoma cells. J Virol (1991) 65:2979-2986.
44. Akgün E, Ziegler M, Grez M: Determinants of retrovirus gene expression in embryonal carcinoma cells. J Virol (1991) 65:382-388.
45. Flanagan JR, Becker KG, Ennist DL, Gleason SL, Driggers PH, Levi BZ, Appella E, Ozato K: Cloning of a negative transcription factor that binds to the upstream conserved region of Moloney murine leukemia virus. Mol Cell Biol (1992) 12:38-44.
46. Becker KG, Jedlicka P, Templeton NS, Liotta L, Ozato K: Characterization of hUCRBP (YY1, NF-E1, delta): A transcription factor that binds the regulatory regions of many viral and cellular genes. Gene (1994) 150:259-266.
47. Challita PM, Skelton D, el-Khoueiry A, Yu XJ, Weinberg K, Kohn DB: Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol (1995) 69:748-755.
48. Auten J, Agarwal M, Chen J, Sutton R, Plavec I: Effect of scaffold attachment region on transgene expression In retrovirus vector-transduced primary T-cells and macrophages. Hum Gene Ther (1999) 10:1389-1399.
49. Plavec I: Scaffold attatchment region encoding retroviral vectors for improved expression in human hematopoietic cells. Second Conference of the American Society for Gene Therapy, Washington DC, June 9-13 (1999):Abs 949.
50. Pikaart MJ, Recillas-Targa F, Felsenfeld G: Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators. Genes Dev (1998) 12:2852-2862.
51. Kim SH, Yu SS, Park JS, Robbins PD, An CS, Kim S: Construction of retroviral vectors with improved safety, gene expression, and versatility. J Virol (1998) 72:994-1004.
52. Hildinger M, Abel KL, Ostertag W, Baum C: Design of 5′ untranslated sequences in retroviral vectors developed for medical use. J Virol (1999) 73:4083-4089.
53. Yen TS: Posttranscriptional regulation of gene expression in hepadnaviruses. Semin Virol (1998) 8:319-326.
54. Zufferey R, Donello JE, Trono D, Hope TJ: Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol (1999) 73:2886-2892.
55. Grande A, Piovani B, Aiuti A, Ottolenghi S, Mavilio F, Ferrari G: Transcriptional targeting of retroviral vectors to the erythroblastic progeny of transduced hematopoietic stem cells. Blood (1999) 93:3276-3285.